Alzheimer's disease & dementia

Highly awaited Alzheimer's drug hit by delays

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Medications

Biogen pulls controversial Alzheimer's drug Aduhelm

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

Cardiology

Research reveals new hope for obesity-induced heart disease

Obesity-induced heart disease, which affects up to 10% of the population in certain age ranges, is considered an untreatable condition and 75% of people don't survive more than five years beyond diagnosis.

page 1 from 37